www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html

Preview meta tags from the www.aafp.org website.

Linked Hostnames

1

Thumbnail

Search Engine Appearance

Google

https://www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html

Acute Migraine Headache: Treatment Strategies

Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.



Bing

Acute Migraine Headache: Treatment Strategies

https://www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html

Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.



DuckDuckGo

https://www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html

Acute Migraine Headache: Treatment Strategies

Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.

  • General Meta Tags

    31
    • title
      Acute Migraine Headache: Treatment Strategies | AAFP
    • charset
      UTF-8
    • description
      Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.
    • template
      aafp-article-page
    • tags
      aafp:publications/afp/article-types/feature,aafp:taxonomy/afp/headache,aafp:publications/afp/topics/headache/treatment,aafp:publications/filters/discipline/neurologic,aafp:publications/filters/content-focus/treatment
  • Open Graph Meta Tags

    6
    • og:title
      Acute Migraine Headache: Treatment Strategies
    • og:description
      Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.
    • og:image
      https://www.aafp.org/dam/brand/aafp/pubs/afp/issues/2025/0400/wiley.jpg
    • og:image:alt
      AAFP logo in blue with orange flame in torch
    • og:url
      https://www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html
  • Twitter Meta Tags

    6
    • twitter:card
      summary_large_image
    • twitter:site
      @aafp
    • twitter:title
      Acute Migraine Headache: Treatment Strategies
    • twitter:description
      Migraine is a primary headache disorder characterized by recurrent disabling attacks. Pharmacologic treatment of acute migraine episodes should be individualized based on route of administration, cost, contraindications, and adverse effects. Stratifying treatment based on migraine severity may result in more rapid resolution of symptoms and return of function. Simple analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs, are first-line treatments for mild to moderate migraine episodes, and triptans are first-line therapy for moderate to severe attacks. Antiemetics and ergot alkaloids are recommended as second-line agents and in cases of refractory migraine. Gepants and ditans are promising newer agents that are supported by quality evidence for second-line use. Unlike triptans and ergot alkaloids, gepants and ditans do not have vascular contraindications. The use of these medications is largely limited by cost, although the adverse effects of ditans also may limit their use. Opioids and butalbital-containing medications are not recommended for the treatment of migraine unless other options have been ineffective. There is insufficient evidence to recommend nonpharmacologic therapies, such as neuromodulatory devices, acupuncture, and greater occipital nerve blocks, but these therapies may be appropriate for select patients.
    • twitter:image
      https://www.aafp.org/dam/brand/aafp/pubs/afp/issues/2025/0400/wiley.jpg
  • Link Tags

    25
    • canonical
      https://www.aafp.org/pubs/afp/issues/2025/0400/acute-migraine-headache.html
    • preconnect
      https://ssl.aafp.org
    • preconnect
      https://img.aafp.net
    • preconnect
      https://css.aafp.net
    • preconnect
      https://js.aafp.net

Links

5